Lege Artis Medicinae

[Increasing importance of invasive fungal diseases]

PRINZ Gyula, SINKÓ János

MAY 20, 2011

Lege Artis Medicinae - 2011;21(05)

[INTRODUCTION - Invasive mycoses are life-threatening fungal infections affecting patients with severe underlying conditions or impaired immune system. According to epidemiological studies, the incidence of invasive mycosis is increasing in several patient groups. CASE REPORT - In patients who require ICU care, the majority of invasive mycoses are caused by Candida species. A shift has been observed within the spectrum of pathogenic species. In patients undergoing chemotherapy for acute leukemia and in recipients of allogenic stem cell transplantation, however, an increased morbidity and mortality of invasive aspergillosis have been observed. The authors discuss current issues regarding the diagnosis and treatment of invasive fungal diseases on the basis of case reports. CONCLUSION - Invasive mycoses are lifethreatening infections affecting patients with severe underlying conditions. While the opportunities of state-of-the-art medicine are expanding, the incidence and significance of these infections increases. If detected and treated in time with appropriate antifungal agents, these infections can be efficiently treated.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Man is not Made for Defeat – Hemingway’s Pathography]

KISS László

Lege Artis Medicinae

[Relationship Networks]

BUDA Béla

Lege Artis Medicinae

[Psychological Approaches to the Psychedelic Experience: James Maslow and Transpersonal Psychology Part I ]

SZUMMER Csaba

Lege Artis Medicinae

[To fight for our self-esteem as well]

PAPP Magor

Lege Artis Medicinae

[The modern disciplines of diagnosing and treating back pain]

BÁLINT Géza

[The author presents the recommendations of international guidelines in the modern diagnosis and treatment of low back pain. Regarding diagnosis, it is very important to differentiate between “specific” and “aspecific” or “nonspecific” low back pain. The term “specific low back pain” includes all diseases and pathologies with well-defined aetiology and pathological process, including bacterial spondylitis, rheumatic spondylarthropathies, primary or secondary tumours, malignancies, myelon- or cauda equine compression, paresis, metabolic base diseases, pathological or nonpathological fractures are suspected. The presence of so called “red flags” indicate“specific” low back pain. This type of low back pain requires quick and precise diagnosis and specific treatment. All other kinds of low back pain, even those with very painful radiculopathy, and without paresis, cauda- or myelon compression can be considered as aspecific, even if caused by a herniated disc, because there is no absolute indication of discectomy. In case of aspecific low back pain, there is no need of any diagnostic imaging methods, because they would not influence treatment. The main points of treatment are to keep the patient active, quick mobilisation with appropriate analgesia and antiinflammatory treatment following no more than 2-3 days of bed rest, and return to work as soon as possible, with easier work conditions if needed. The longer the patient is on sick leave, the higher the risk he or she will never return to work. If initial active treatment is not is effective enough, the patient's case should be reassessed in 3-6 weeks. If a herniated disc is suspected, the necessary imaging methods should be performed, and the patient should be operated if necessary. With this method, chronic, disabling low back pain can be avoided in many cases. The danger of developing chronic low back pain are indicated by the so called “yellow flags”: dissatisfaction with work, allowance claim, insufficient and even false ideas about the causes and consequences of low back pain, fear, anxiety, depression. These problems can be alleviated by the positive athmosphere of the workplace, appropriate patient education, activity, anxiolytic and antidepressant drugs, activity and regular exercise.]

All articles in the issue

Related contents

Lege Artis Medicinae

[Empirical versus preemptive antifungal therapy of invasive fungal infections in patients with oncohaematological diseases]

RÓKUSZ László

[Fungal infections present a significant problem among immunocompromised patients. The essence of empirical antifungal therapy is to collect data, physical signs and symptoms that confirm the clinically suspected invasive fungal infections and enable initiation of antifungal therapy. With the improvement of early diagnosis of invasive fungal infactions, the diagnosisdrived application of antifungal preparations has been re-evaluated. However, no consensus exists to date regarding preemptive antifungal therapy. After evaluating the benefits and potential side effects of the therapy, the relevant centers decide whether the preemptive or the empirical method should be preferred.]

Lege Artis Medicinae

[The role of measuring galactomannan in the modern therapy of invasive aspergillosis]

SINKÓ János

[Invasive aspergillosis is a life threatening mycosis prevalent in groups of patients with specific risk factors. To establish the diagnosis a specimen for histological examination has to be obtained. However, the vast majority of patients are not suitable for biopsy or this procedure can only be performed late in the course of the disease. Current diagnostic workup is based on high resolution thoracic CT scans and serum galactomannan antigen testing. Antigen detection can either be used for screening to detect early phase infection or to prove the full-blown disease. Here clinical aspects of galactomannan antigen testing and its role in current management of aspergillosis are reviewed.]

Lege Artis Medicinae

[Treatment of invasive fungal infections: present and future]

SINKÓ János

[In immunocompromised patients morbidity and mortality caused by invasive fungal infections is increasing. It is difficult to establish early diagnosis of mycosis by laboratory tests currently available. Antifungal drugs are often toxic, their spectrum of action is limited and their cost is substantial. In the search for alternative therapeutic modalities, antifungal compounds were synthesised against several targets of the fungal cell. At present, the following drugs have almost completed drug registration procedures: voriconazole, posaconazole and ravuconazole from the new azol group, a candin named caspofungin, and the polyene liposomal nystatin. Nikkomycin Z, sordarins and some other compounds are also seem to be promising. In addition to new antifungal drugs, substantial improvement in the outcome of invasive fungal infections requires extended diagnostic capabilities, as well as a reappraisal of our principles of prophylaxis and treatment.]